Clinical trial
The Mito-Frail Trial: Effects of MitoQ on Vasodilation, Mobility and Cognitive Performance in Frail Older Adults
Name
23-132S-1
Description
The goal of this clinical trial is to test the effects of MitoQ supplementation in older adults and frail older adults with physical dysfunction and/or cognitive dysfunction. The main question\[s\] it aims to answer are:
* To compare vascular function, oxidative stress levels, and physical and cognitive function among older adults and frail older adults with physical and cognitive dysfunction
* To determine whether MitoQ supplementation has the potential to improve vascular function in central and cerebral vessels
* To determine whether MitoQ supplementation can enhance physical and cognitive capabilities.
Trial arms
Trial start
2024-02-28
Estimated PCD
2025-09-01
Trial end
2027-07-01
Status
Not yet recruiting
Phase
Early phase I
Treatment
Mitoquinone Mesylate
MitoQ given 20 mg per day for 12 weeks.
Arms:
MitoQ capsule
Placebo capsule
Placebo capsule taken every day for 12 weeks.
Arms:
Placebo capsule
Size
60
Primary endpoint
Change in Vascular Endothelial Function
4 visits : Baseline, 12 weeks (MitoQ or Placebo), 8 weeks washout, 12 weeks (MitoQ or Placebo)
Change in Cerebrovascular Function
4 visits : Baseline, 12 weeks (MitoQ or Placebo), 8 weeks washout, 12 weeks (MitoQ or Placebo)
Change in NIH Tool Box Composite
4 visits : Baseline, 12 weeks (MitoQ or Placebo), 8 weeks washout, 12 weeks (MitoQ or Placebo)
Change in walking speed
4 visits : Baseline, 12 weeks (MitoQ or Placebo), 8 weeks washout, 12 weeks (MitoQ or Placebo)
Sensitivity of a Montreal Cognitive Assessment score
4 visits : Baseline, 12 weeks (MitoQ or Placebo), 8 weeks washout, 12 weeks (MitoQ or Placebo)
Eligibility criteria
Inclusion Criteria:
* men and women aged 65-80 with a slow gait speed (0.4m/s based on a 4m walk) and/or mild cognitive impairment.
* good cardiovascular health (not taking any blood pressure/flow/metabolism altering medications)
Exclusion Criteria:
* A vaccination in past two weeks
* Recent acute infection three weeks prior to enrollment
* Known immunodeficiency (including HIV infection, primary immunodeficiency, any history of chemotherapy or radiotherapy
* Use of medicines during past 6 months known to alter immune response such as high- dose corticosteroids
* Severe autoimmune disease requiring biological therapy
* Major severe illness and/or Hospitalization in past 3 months
* On warfarin or other medications that are considered a blood thinner
* Recent fall or other conditions that will impair ability to complete and/or interpret mobility performance test
* Known bleeding disorder
* Any conditions that would impair the function to perform grip strength test
* include advanced neurological disease, severe co-morbid disease, terminal illness with reduced life expectancy, severe disability, unintentional weight loss in last 12 months and participation in another study.
* Diabetes patients requiring insulin (For reducing the risk that participants will have hypoglycemic episodes when fasting for study visits)
* Baseline ECG QTc \>450 ms in men and QTc \>460 ms in women
* Prior diagnosis of ventricular arrhythmia (e.g., ventricular tachycardia, ventricular fibrillation, torsades de pointes)
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE2'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'CROSSOVER', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'TRIPLE', 'maskingDescription': 'Double-blind, placebo-controlled', 'whoMasked': ['PARTICIPANT', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 60, 'type': 'ESTIMATED'}}
Updated at
2024-02-12
1 organization
1 product
3 indications
Organization
UConn HealthProduct
MitoquinoneIndication
frailtyIndication
Mild Cognitive ImpairmentIndication
Aging